Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corcelle, E.
Right arrow Articles by Mograbi, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corcelle, E.
Right arrow Articles by Mograbi, B.
[Cancer Research 66, 6861-6870, July 1, 2006]
© 2006 American Association for Cancer Research


Epidemiology and Prevention

Disruption of Autophagy at the Maturation Step by the Carcinogen Lindane Is Associated with the Sustained Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Activity

Elisabeth Corcelle1,2, Marielle Nebout1, Soumeya Bekri5, Nils Gauthier3, Paul Hofman4, Philippe Poujeol2, Patrick Fénichel1 and Baharia Mograbi1,4

1 Institut National de la Santé et de la Recherche Médicale, INSERM U670, IFR 50, Faculté de Médecine; 2 Centre National de la Recherche Scientifique Unité Mixte de Recherche 6548, Faculté des Sciences; 3 Institut National de la Santé et de la Recherche Médicale, U627, IFR 50; 4 Institut National de la Santé et de la Recherche Médicale/Région Provence Alpes Côte d' Azur, ESPRI 2006/Laboratoire de Pathologie Clinique et Expérimentale, Hôpital Pasteur, Nice, France; and 5 Groupe Appareil Digestif et Environnement (EA3234), Faculté de Médecine, Rouen, France

Requests for reprints: Baharia Mograbi, Institut National de la Santé et de la Recherche Médicale ESPRI 2006, IFR 50, Faculté de Médecine, Avenue de Valombrose, 06107 Nice Cedex 02, France. Phone: 33-4-93-37-77-94; Fax: 33-4-93-37-77-52; E-mail: mograbi{at}hermes.unice.fr.

Macroautophagy (hereafter referred to as autophagy) has emerged as a key tumor suppressor pathway. During this process, the cytosolic constituents are sequestered into autophagosomes, which subsequently fuse with lysosomes to become autolysosomes where their contents are finally degraded. Although a reduced autophagy has been shown in human tumors or in response to oncogenes and carcinogens, the underlying mechanism(s) remain(s) unknown. Here, we show that widely used carcinogen Lindane promotes vacuolation of Sertoli cells. By electron and immunofluorescent microscopy analyses, we showed that these structures are acid autolysosomes, containing cellular debris, and labeled by LC3, Rab7, and LAMP1, markers of autophagosomes, late endosomes, and lysosomes, respectively. Such Lindane-induced vacuolation results from significant delay in autophagy degradation, in relation with a decline of the lysosomal activity of aryl sulfatase A. At molecular level, we show that this defect in autolysosomal maturation is independent of mammalian target of rapamycin and p38 inhibitions. Rather, the activation of the mitogen-activated protein kinase (MAPK)/extracellular signal–regulated kinase (ERK) pathway is required for Lindane to disrupt the autophagic pathway. Most importantly, we provide the first evidence that sustained activation of ERK pathway is sufficient to commit cell to autophagic vacuolation. Taken together, these findings strongly support that the aberrant sustained activation of ERK by the carcinogen Lindane disrupts the maturation of autophagosomes into functional autolysosomes. Our findings therefore suggest the possibility that high constitutive ERK activity found in all cancers may provide a malignant advantage by impeding the tumor suppressive function of autophagy. (Cancer Res 2006; 66(13): 6861-70)




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. K. Amaravadi and C. B. Thompson
The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment
Clin. Cancer Res., December 15, 2007; 13(24): 7271 - 7279.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. M. B. Nguyen, I. V. Subramanian, A. Kelekar, and S. Ramakrishnan
Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells
Blood, June 1, 2007; 109(11): 4793 - 4802.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.